Serum and CSF levels of IL-2, sIL-2R, TNF-α, and IL-lβ in chronic progressive multiple sclerosis: Expected lack of clinical utility

Neurology

Volumn 41, Issue 1, 1991, Pages 121-123

  Peter, James B ^a   Boctor, Fouad N ^a   Tourtellotte, Wallace W ^b  

^a Specialty Laboratories   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECEPTOR SOLUBILIZATION; SERUM;

CHRONIC DISEASE; HUMAN; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKINS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; RECEPTORS, INTERLEUKIN-2; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TUMOR NECROSIS FACTOR;

EID: 0025976467     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.41.1.121     Document Type: Article

References (18)

1. Gallo P, Piccinno N, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1988;24:795-797.
2. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis [Letter]. N Engl J Med 1988;319:1019-1020.
3. Trotter JL, Clifford DB, Anderson CB, van der Veen RC, Hicks BC, Bank G. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis [Letter], N Engl J Med 1988;318:1206.
4. Trotter JL, Clifford DB, Mclnnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989;25:172-178.
5. Clifford DB, Trotter JL, van der Veen RC. Serial cytokine levels in chronic progressive MS patients [Abstract]. Neurology 1990;40(suppl 1):333.
6. Gallo P, Piccinno MG, Krzalic Lj Tavolato B. Tumor necrosis factor alpha (TNFa) and neurological disease. Failure in detecting TNFa in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. J Neuroim- munol 1989;23:41-44.
7. Gallo P, Piccinno MG, Pagni S, et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and y-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989;92:9-15.
8. Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicating relapse in multiple sclerosis [Letter]. Lancet 1989;1:559-560.
9. Franciotta DM, Grimaldi LME, Martino GV, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989;26:787-789.
10. Hartung H-P, Hughes RAC, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990;40:215-218.
11. Capra R, Mattioli F, Marciano N, et al. Significantly higher levels of soluble interleukin 2 in patients with relapsing-remitting multiple sclerosis compared with healthy subjects [Letter]. Arch Neurol 1990;47:254.
12. Dinarello CA, Mier JW. Current concepts: lymphokines. N Engl J Med 1987;317:940-945.
13. Malkovsky M, Sondel PM, Strober W, Dalgleish AG. The interleukins in acquired disease. Clin Exp Immunol 1988;74:151-161.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
16. Braitman LE. Confidence intervals extract clinically useful information from data. Ann Intern Med 1988;108:296-298.
17. Diem K, Lentner C, eds. Scientific tables, 7th ed. Geigy Pharmaceuticals, Division of CIBA-Geigy Corporation, Ardsley, NY: 1970:85-103.
18. Rudick RA, Barna BP. Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue [Letter], Arch Neurol 1990;47:254-255.